Medtronic 006002INT Instructions for Use

Progenix™ Putty and Progenix™

M708348B778E Rev. C

Plus

2022-04-20

IMPORTANT INFORMATION ON PROGENIX™ PUTTY AND PROGENIX™ PLUS

This package contains donated human allograft tissue intended for transplantation.

DESCRIPTION

Progenix™ products contain human Demineralized Bone Matrix (DBM) in a biocompatible carrier. The carrier is a mixture of
bovine collagen with a natural polysaccharide (sodium alginate). The components are mixed in phosphate buffered saline to
achieve a flow-able or moldable consistency. Progenix™ is available in two forms: Putty and Plus. Progenix™ Plus contains two
different sized demineralized bone particles.

Progenix™ Putty and Progenix™ Plus are single use products intended for filling bony voids or gaps of the skeletal system and
oralmaxillofacial region not intrinsic to the stability of the bony structure. These products are not designed to impart any
mechanical strength to the surgical site. Both versions are provided in ready-to-use malleable forms that may be molded or
manipulated by the surgeon into various shapes. These products have been shown to be osteoinductive in an athymic rat
assay, as well as osteoconductive, allowing for bony ingrowth across the graft site while resorbing at a rate consistent with bony
healing.

Implied warranties of merchantability and fitness for a particular purpose or use are specifically excluded.

INDICATIONS FOR SPINE, PELVIS, AND EXTREMITIES

Progenix™ Putty and Progenix™ Plus are intended for use as a bone graft substitute in bony voids or gaps of the skeletal
system not intrinsic to the stability of the bony structure (i.e. spine, pelvis, and extremities). The voids or gaps may be surgically
created osseous defects or osseous defects created from traumatic injury to the bone. Progenix™ Putty and Progenix™ Plus
provide a bone void filler that is resorbed/remodeled and replaced by host bone during the healing process. When used in the
extremities or pelvis, Progenix™ Putty is used by itself. When Progenix™ Putty is used in the spine, the device must be mixed
with autograft bone and used as a bone graft extender. Progenix™ Plus may either be used alone or mixed with autograft bone
and used as a bone graft extender.

INDICATIONS FOR CRANIAL AND ORALMAXILLOFACIAL

Progenix™ Putty and Progenix™ Plus may be used alone or in combination with autograft bone or autogenous bone marrow for
use as a bone graft extender, substitute, and bone void filler in bony voids or gaps not intrinsic to the stability of the bony
structure of the cranial, oral, and maxillofacial region. The voids or gaps may be surgically created osseous defects or osseous
defects created from traumatic injury to the bone. Progenix™ Putty and Progenix™ Plus provide a bone void filler that is
resorbed/remodeled and is replaced by host bone during the healing process.

Progenix™ Putty and Progenix™ Plus may be used alone or in combination with autogenous bone or bone marrow aspirate for
the augmentation of deficient maxillary and mandibular alveolar ridges and the treatment of cranial, oralmaxillofacial, and dental
intraosseous defects including:

▪ Ridge augmentation.
▪ Filling of cystic defect.
▪ Filling of extraction sites.
▪ Filling of lesions of periodontal origin.
▪ Craniofacial augmentation.
▪ Filling of defects of endodontic origin.
▪ Mandibular reconstruction.
▪ Repair of traumatic defects of the alveolar ridge, excluding maxillary and mandibular fracture.
▪ Filling of resection defects in benign bone tumors, benign cysts, or other osseous defects in the alveolar ridge wall.

Note: the user should consider the fact that Progenix™ Plus contains demineralized bone chips approximately 2-4mm when
determining the appropriateness of this allograft for use in small defects.

CONTRAINDICATIONS

These products are contraindicated, and should not be used, in patients who have known allergies to bovine collagen, sodium
alginate, polymyxin, or bacitracin antibiotics.

These products do not possess sufficient mechanical strength to support the reduction of a defect site prior to soft and hard
tissue ingrowth. These products are contraindicated where stabilization of the defect is not possible.

POTENTIAL ADVERSE EVENTS

Donor screening methods are limited. Therefore, certain diseases may not be detected. The following complications of tissue
transplantation may occur:

▪ Transmission or causation of diseases of unknown etiology and characteristics.
▪ Transmission of known infectious agents including HIV, Hepatitis B, Hepatitis C, syphilis, and bacteria.
▪ Immune rejection of transplanted grafts.
▪ Loss of function or integrity of transplanted tissue due to resorption, fragmentation, or disintegration including associated

loss of continuity, displacement, bending, or fracture.

All of the same medical/surgical conditions that may complicate any surgical procedure may occur during or following the
transplantation of an allograft. Neither the manufacturer nor its affiliates expressly or by implication warrant any tissue selected,
recovered, processed, or distributed by itself, distributors, representatives, or agents. Any adverse outcomes potentially
attributable to Progenix must be promptly reported to Medtronic at [phone] or [phone].

WARNINGS AND PRECAUTIONS

A small number of patients may experience localized immunological reactions resulting from the use of this device (e.g.
transient localized edema and swelling, and rash). The safety and effectiveness of the device in these patients has not been
established.

Over-pressurizing the device may result in extrusion beyond the site of its intended application and may damage the
surrounding tissues.

Over-pressurizing the defect site may lead to fat embolization or embolization of the device’s material into the bloodstream.

For US Audiences Only
Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.
Physician and dentist note: although physicians and dentists are the learned intermediary between the company and the

patient, the important medical information given in this document should be conveyed to the patient.

DONOR SCREENING AND TESTING

The tissue donor, from whom this allograft was derived, was screened for high risk factors, clinical signs, and symptoms of HIV,
hepatitis, CJD/vCJD and other diseases and medical conditions that would contraindicate the donation of tissues in accordance
with current FDA regulations and guidance documents, state regulations, standards established by the American Association of
Tissue Banks, and current US Public Health Services recommendations.

Donor blood samples taken at the time of recovery were tested for communicable disease by a laboratory registered with the
FDA to perform donor testing and certified to perform such testing on human specimens under the Clinical Laboratory
Improvement Amendments of 1988 (CLIA) (42 U.S.C. 263a) and 42 CFR Part 493 using FDA approved, licensed, or cleared
tests including:

HBsAg Hepatitis B Surface Antigen
HBc-IgM/IgG Hepatitis B Total Core Antibody
HCV Hepatitis C Antibody
HIV 1/2-Ab Antibody to Human Immunodeficiency Virus Types 1 and 2
RPR/STS or Equivalent Syphilis Detection
HIV 1 NAT Human immunodeficiency virus type 1 nucleic acid amplification testing
HCV NAT Hepatitis C virus nucleic acid amplification testing
HTLV I/II Human T-Lymphotropic Virus Types I and II

The results of all the relevant communicable disease tests referenced above were found to be negative or non-reactive.
In addition to the tests listed above, other tests may have been performed including tests for HBV NAT (Hepatitis B virus nucleic

acid amplification testing) and WNV NAT (West Nile Virus nucleic acid amplification testing). If HBV NAT and WNV NAT tests
were performed, the results of these tests were negative or non-reactive, and the results of any other tests performed were
negative or otherwise acceptable for eligibility of donors of musculoskeletal tissues.

The communicable disease test results, together with the informed consent, medical and social history interview, physical
assessment, available medical records (to include previous medical history, laboratory test results, autopsy and coroner reports,
if performed), and information obtained from any source or records which may pertain to donor eligibility, were evaluated by a
Medical Director of Community Tissue Services, Dayton, OH, 45402. Based on this evaluation, the donor was determined to
meet donor eligibility criteria current at the time of recovery. The donor eligibility criteria used to screen this donor are in
compliance with FDA regulations published in 21 CFR Part 1271 “Human Cells, Tissues, and Cellular and Tissue-Based
Products”.

The names and addresses of the testing laboratories, the listing and interpretation of all required communicable disease tests, a
listing of the documents reviewed as part of the relevant medical records, and the name of the person or establishment
determining the eligibility of this human tissue are on file at Medtronic and are available upon request.

The final, processed tissue allograft was released for transplantation based on the initial donor eligibility determination and on a
post-processing review and determination that the allograft met all processing requirements and allograft specifications.